Siam Oottamasathien

Dr. Siam Oottamasathien


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DSDouglas Steinhauff
Douglas Steinhauff
MJMark Martin Jensen
Mark Martin Jensen
EGEthan Griswold
Ethan Griswold
JJJolanta Jedrzkiewicz
Jolanta Jedrzkiewicz
JCJoseph Cappello
Joseph Cappello
HGHamidreza Ghandehari
Hamidreza Ghandehari
Semisynthetic glycosaminoglycan ethers (SAGEs) are short, sulfated hyaluronans which combine the natural properties of hyaluronan with chemical sulfation. In a murine model, SAGEs provide protection against radiation induced proctitis (RIP), a side effect of lower abdominal radiotherapy for cancer. The anti-inflammatory effects of SAGE have been studied in inflammatory diseases at mucosal barrier sites; however, few mechanisms have been uncovered necessitating high throughput methods. SAGEs were combined with silk-elastinlike polymers (SELPs) to enhance rectal accumulation in mice. After high radiation exposure to the lower abdominal area, mice were followed for 3 days or until they met humane endpoints, before evaluation of behavioral pain responses and histological assessment of rectal inflammation. RNA sequencing was conducted on tissues from the 3-day cohort to determine molecular mechanisms of SAGE–SELP. After 3 days, mice receiving the SAGE–SELP combination yielded significantly lowered pain responses and amelioration of radiation-induced rectal inflammation. Mice receiving the drug–polymer combination survived 60% longer than other irradiated mice, with a fraction exhibiting long term survival. Sequencing reveals varied regulation of toll like receptors, antioxidant activities, T-cell signaling, and pathways associated with pain. This investigation elucidates several molecular mechanisms of SAGEs and exhibits promising measures for prevention of RIP.

27 February 2026 in Bladder
Verified
Journal Article
Open access
PDF file
ASAustin James Schults
Austin James Schults
MJMark Martin Jensen
Mark Martin Jensen
WJWanjian Jia
Wanjian Jia
SOSiam Oottamasathien
Siam Oottamasathien
Background: Chronic bladder pain in interstitial cystitis often persists without overt inflammation, highlighting the need for physiologically relevant experimental models and effective non-opioid therapies. Objective: This study aims to evaluate the impact of persistent inflammation on bladder pain using an LL-37–induced murine model of interstitial cystitis/painful bladder syndrome (IC/PBS). We hypothesized that chronic pain could develop independently of ongoing inflammation and that a sulfated glycosaminoglycan ether (SAGE) compound could attenuate the pain and inflammation elicited by LL-37. Methods: Female C57BL/6 mouse bladders were instilled biweekly with 80 μM LL-37, a human antimicrobial peptide with immunomodulatory properties, for 1 h over four weeks. The analgesic efficacy of SAGE GM-0111, a sulfated hyaluronic acid derivative, was assessed by intravesical instillation immediately prior to LL-37 exposure. Pain responses were quantified using von Frey filaments (0.04–4.0 g). Inflammation and fibrosis were evaluated via myeloperoxidase and total collagen assays, gross examination, and histological analysis. Results: LL-37–treated animals exhibited significantly elevated pain responses (98.00 ± 0.42% positive response) compared to repeated saline controls (55.00 ± 3.80%; p < 0.001) and SAGE GM-0111–treated animals (54.17 ± 3.28%; p < 0.01). Despite pronounced hyperalgesia, no significant inflammation or fibrosis was detected by myeloperoxidase and collagen assays or histological evaluation. Conclusion: Repeated intravesical LL-37 administration induces a chronic pain phenotype that closely models human IC/PBS, wherein bladder pain occurs independently of overt inflammation. Furthermore, SAGE GM-0111 exerts significant analgesic effects in this model. This platform provides a valuable tool for elucidating mechanisms underlying bladder pain in IC/PBS, particularly in cases lacking evident inflammation or fibrosis.

11 October 2025 in Urology Case Reports
Verified
Journal Article
Open access
DADaniel Ajabshir
Daniel Ajabshir
KSKenneth Softness
Kenneth Softness
SOSiam Oottamasathien
Siam Oottamasathien
We present a rare case of recurrent idiopathic ischemic priapism in a healthy 14-year-old male with no identifiable risk factors such as hematologic disorders, trauma, or medication use. The patient required surgical intervention after failing conservative measures, including aspiration and intracavernosal phenylephrine. A bilateral T-shunt ultimately achieved successful detumescence. Postoperative rehabilitation with tadalafil and a vacuum erection device preserved erectile function. This case highlights the importance of early recognition and a stepwise approach to pediatric priapism. It also raises the possibility of a novel association between chronic constipation and impaired venous outflow contributing to priapism in children.